Overland Pharma Joint Venture with ADC Therapeutics

December 14, 2020Client News

Gunderson Dettmer represented client Overland Pharma in its joint venture with ADC Therapeutics forming new company, Overland ADCT BioPharma (CY) Limited, that will develop and commercialize four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors in greater China and Singapore.

In the announcement of the transaction, co-founder and chief medical officer of Overland Pharmaceuticals Hua Mu said, “We are pleased to work with ADC Therapeutics, a pioneer in the field of ADCs, on this strategic venture to enable the development and commercialization of multiple targeted therapies for the treatment of patients with difficult-to-treat hematological and solid tumor cancers in greater China and Singapore.”

The Gunderson deal team was led by Tim Ehrlich and included Peter Schoch, Stephen Wheeler and Kelvin Chan.